|
Malignant neoplasm of prostate
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
ESR2 (CA)(n) showed no effects on prostate cancer risk.
|
18006911 |
2007 |
|
Malignant neoplasm of prostate
|
0.400 |
Biomarker
|
disease |
BEFREE |
ERβ is epigenetically silenced in prostate cancer patients, therefore our results suggest that combination of ERβ agonists with ADT would benefit men stratified on the basis of high estrogen levels.
|
25816367 |
2015 |
|
Malignant neoplasm of prostate
|
0.400 |
Biomarker
|
disease |
BEFREE |
ERβ is commonly studied in MCF-7 (breast) and LNCaP (prostate) cancer cell lines, but we found no ERβ expression in either, using validated antibodies and independent mass spectrometry-based approaches.
|
27889472 |
2017 |
|
Malignant neoplasm of prostate
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Estrogen receptor beta (ERβ) splice variants are implicated in prostate cancer (PC) progression; however their underlying mechanisms remain elusive.
|
28968951 |
2017 |
|
Malignant neoplasm of prostate
|
0.400 |
Biomarker
|
disease |
BEFREE |
A total of 43 tagging single nucleotide polymorphisms covering the loci of AR (n = 4), ESR1 (n = 32), and ESR2 (n = 7) were successfully genotyped in 4,073 prostate cancer cases.
|
20615892 |
2010 |
|
Malignant neoplasm of prostate
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Additionally, FTY720 abolished estrogen-stimulated expression of ERα and basal expression of ERβ within prostate cancer cells.
|
29654831 |
2018 |
|
Malignant neoplasm of prostate
|
0.400 |
Biomarker
|
disease |
BEFREE |
Although it is speculated that ERα is associated with harmful effects on PCa, the role of ERβ in PCa is still ill-defined.
|
28503095 |
2017 |
|
Malignant neoplasm of prostate
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Although primary human PCa-associated fibroblasts and the human WPMY-1-reactive prostate stromal cell line maintain this inherent estrogen receptor (ER)β-dependent motility inhibitor activity, they are subverted by TGF-β1 pro-oxidant signals derived from cocultured DU145 PCa cells.
|
22593181 |
2012 |
|
Malignant neoplasm of prostate
|
0.400 |
Biomarker
|
disease |
BEFREE |
Although, an increasing body of evidence has linked estrogen receptor beta (ERß) to prostate cancer, the function of estrogen receptor alpha (ERα) in prostate cancer is not very well studied.
|
26575018 |
2015 |
|
Malignant neoplasm of prostate
|
0.400 |
Biomarker
|
disease |
BEFREE |
Altogether, the data showed that (a) circulating testosterone may act with estrogenic effects downstream in the catabolic process present in the prostate, and (b) that the estrogenic effect of testosterone derivatives (ERbeta-dependent) results in the inhibition of cell migration, although it is apparently different from that linked to estradiol on the same receptor and may be protective against prostate cancer invasion and metastasis.
|
15958594 |
2005 |
|
Malignant neoplasm of prostate
|
0.400 |
Biomarker
|
disease |
CTD_human |
Apigenin suppresses cancer cell growth through ERbeta.
|
17132221 |
2006 |
|
Malignant neoplasm of prostate
|
0.400 |
Therapeutic
|
disease |
CTD_human |
Apigenin suppresses cancer cell growth through ERbeta.
|
17132221 |
2006 |
|
Malignant neoplasm of prostate
|
0.400 |
Biomarker
|
disease |
BEFREE |
Based on our recent finding of anti-estrogen/ER-beta-mediated growth inhibition of prostate cancer cells in vitro, the presence of ER-beta in metastatic cells may have important implications for the treatment of late-stage disease.
|
11438457 |
2001 |
|
Malignant neoplasm of prostate
|
0.400 |
Biomarker
|
disease |
BEFREE |
Clinical significance of estrogen receptor β in breast and prostate cancer from biological aspects.
|
25611678 |
2015 |
|
Malignant neoplasm of prostate
|
0.400 |
Biomarker
|
disease |
BEFREE |
Considering a combination marker panel of MCAM, ERα and ERβ increased the sensitivity to 75% and the specificity became 70% for the minimally invasive early detection test of PC.
|
28147335 |
2017 |
|
Malignant neoplasm of prostate
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Differential expression of estrogen receptor beta isoforms in prostate cancer through interplay between transcriptional and translational regulation.
|
23806560 |
2013 |
|
Malignant neoplasm of prostate
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Differential expression profile analysis of ERβ was analyzed by quantitative immunohistochemistry using ethnicity-based tissue microarray encompassing 300 PCa tissue cores.
|
23658372 |
2013 |
|
Malignant neoplasm of prostate
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
Dynamic regulation of estrogen receptor-beta expression by DNA methylation during prostate cancer development and metastasis.
|
15161636 |
2004 |
|
Malignant neoplasm of prostate
|
0.400 |
Biomarker
|
disease |
BEFREE |
ERalpha and ERbeta may play important roles in the development of prostate cancer.
|
17908481 |
2007 |
|
Malignant neoplasm of prostate
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
ERbeta levels were diminished in prostate cancer and loss of ERbeta was associated with proliferation.
|
17913855 |
2007 |
|
Malignant neoplasm of prostate
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Genistein induced phosphorylation, nuclear translocation and transcriptional activity of ER-β in all three PCa cell lines.
|
25931004 |
2015 |
|
Malignant neoplasm of prostate
|
0.400 |
Biomarker
|
disease |
BEFREE |
Here, we focus on estrogen receptor (ER)β, which has promise as a selective target in hormone replacement therapy, and in breast and prostate cancers.
|
27979317 |
2017 |
|
Malignant neoplasm of prostate
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Here, we show the predominant estrogen receptor (ER) isoform expressed in PCa specimens and cell lines is ERβ.
|
22403175 |
2012 |
|
Malignant neoplasm of prostate
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Higher levels of ZFHX3 and ERβ in human prostate cancer tissue samples correlated with better patient survival.
|
30979864 |
2019 |
|
Malignant neoplasm of prostate
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Immunohistochemical analysis revealed that 17βHSD6 is expressed in ERβ-positive epithelial cells of the human prostate and that, in prostate cancers of Gleason grade higher than 3, both ERβ and 17βHSD6 are undetectable.
|
22114194 |
2011 |